FDA Category I Status: Nicotinamide riboside is listed on Category I of FDA’s interim list of substances that may be used in compounding at Section 503B outsourcing facilities.
Clinically Proven NAD+ Enhancement: Clinical studies have shown nicotinamide riboside increases NAD+ levels in the body, which plays a crucial role in cellular energy production, DNA repair, and overall cellular health.
Age-Related NAD+ Decline: As we age, NAD+ levels naturally decline (Massudi et al., 2012; Janssens et al., 2022), which can contribute to decreased vitality and other signs of aging.
Therapeutic Benefits: Niagen IV (nicotinamide riboside) can help restore NAD+ levels, supporting healthy aging, increased cellular energy, and improved cellular function.
Professional Trust: Trusted by healthcare professionals, Niagen IV may help maintain optimal wellness.